
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 35 |
| Chemical drugs | 3 |
| Synthetic peptide | 3 |
| Proteolysis-targeting chimeras (PROTAC) | 3 |
| Radiopharmaceuticals and diagnostic agent | 2 |
Target |
Mechanism JAK2 degraders |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Bacterial growth inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism JAK2 inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date20 Jul 2024 |
Sponsor / Collaborator |
Start Date16 Oct 2019 |
Sponsor / Collaborator |
Start Date01 Mar 2013 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
Semisynthetic sulfated chitosan(East China University of Science and Technology) | Ischemic stroke More | Preclinical |
DWP-0016 ( HDACs x p53 ) | Neoplasms More | Preclinical |
Secondary Amine Pendant β-Peptide Polymers | Wound Infection More | Preclinical |
Y18 ( S1PR1 ) | Colitis, Ulcerative More | Preclinical |
(Gly0.8Nap0.2)20 | Candidiasis More | Preclinical |





